Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts.
Revenue (Most Recent Fiscal Year) | $377.71M |
Net Income (Most Recent Fiscal Year) | $-132.53M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 5.26 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.02 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -34.72% |
Net Margin (Trailing 12 Months) | -35.09% |
Return on Equity (Trailing 12 Months) | -15.90% |
Return on Assets (Trailing 12 Months) | -9.75% |
Current Ratio (Most Recent Fiscal Quarter) | 5.89 |
Quick Ratio (Most Recent Fiscal Quarter) | 5.89 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $12.04 |
Earnings per Share (Most Recent Fiscal Quarter) | $1.73 |
Earnings per Share (Most Recent Fiscal Year) | $-1.72 |
Diluted Earnings per Share (Trailing 12 Months) | $-1.90 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 81.66M |
Free Float | 78.06M |
Market Capitalization | $1.99B |
Average Volume (Last 20 Days) | 1.23M |
Beta (Past 60 Months) | 1.77 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 4.40% |
Percentage Held By Institutions (Latest 13F Reports) | 99.68% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |